Federal Cannabis Crackdown Validates MMJ International's FDA-Compliant Pharmaceutical Approach
Key Insights
Congress is advancing legislation to close the 2018 Farm Bill loophole by redefining hemp to include all THC variants and banning synthetic cannabinoids, effectively eliminating the gray-market cannabis industry.
MMJ International Holdings (search) emerges as a rare fully compliant company with DEA-licensed laboratories, FDA Orphan Drug Designations for Huntington's Disease (search) and Multiple Sclerosis (search), and approved investigational new drug applications.
The regulatory shift gains validation from an unexpected source as Curaleaf Holdings (search) invokes federal cannabis illegality to avoid a $38 million jury-awarded debt, highlighting the financial risks of state-level operations.
A sweeping federal appropriations bill moving through Congress is poised to eliminate the gray-market cannabis industry that flourished under the 2018 Farm Bill, while validating the pharmaceutical approach of MMJ International Holdings (search), one of the few companies pursuing fully federal-compliant cannabis medicine development.
The legislation, supported by President Trump and backed by a bipartisan coalition of 39 State Attorneys General, redefines hemp to include total THC content across all variants including Delta-8 (search), Delta-10 (search), and THCA (search), while banning synthetic or chemically modified cannabinoids such as THC-O (search), HHC (search), and THCP (search).
Regulatory Framework Transformation
The new appropriations bill establishes a 4-milligram cap on total THC content per container, effectively outlawing the entire intoxicating hemp sector. THC beverages, which typically contain 5-10mg per serving, will become Schedule I substances overnight. Similarly, intoxicating hemp products including gummies, vapes, and tinctures using synthetic THC isomers will be prohibited, along with THCA (search) flower and other "converted THC" products.
Federal enforcement is already underway. On November 6, 2025, the Hillsborough County Sheriff's Office in Tampa conducted coordinated raids on convenience stores selling synthetic cannabinoids and THC gummies, signaling a unified national enforcement priority.
"The government is raiding corner stores while blocking the very scientists who could replace those products with safe, FDA approved alternatives," said Duane Boise, President & CEO of MMJ International Holdings (search). "That's cruelty disguised as process."
Cannabis Industry's Legal Contradiction
The regulatory shift received unexpected validation from within the recreational cannabis industry itself. Curaleaf Holdings (search), Inc., one of the world's largest marijuana operators, is invoking the Controlled Substances Act—the same federal law that makes marijuana illegal—to nullify a contract and avoid paying a $38 million debt awarded by a federal jury.
In February 2025, a federal jury awarded Hello Farms (search), a Michigan grower, $31.8 million plus $5 million in interest in a breach-of-contract case. Curaleaf's appellate brief to the Sixth Circuit Court of Appeals argues the contract is "per se unenforceable" because "federal law unambiguously makes marijuana illegal," claiming the contract constituted a "conspiracy to manufacture and distribute marijuana" in violation of the CSA.
"You cannot make this up," Boise said. "A state operator is now citing the federal illegality of cannabis—the very illegality MMJ has complied with for a decade—to escape a $38 million debt. This is the naked financial risk of the gray market laid bare. The Curaleaf case proves the only stable, legal path for cannabis is through DEA licensure and FDA science."
MMJ's Pharmaceutical Blueprint
As federal enforcement eliminates gray-market competitors, MMJ International Holdings (search) stands positioned with a vertically integrated pharmaceutical model that includes a DEA Schedule I-licensed laboratory (MMJ BioPharma Labs (search)), FDA Orphan Drug Designations for Huntington's Disease (search) and Multiple Sclerosis (search), and GMP-certified manufacturing protocols with FDA IND-approved formulations.
The company has completed development of THC-CBD soft gelatin medicines and maintains two accepted FDA Investigational New Drug applications. This pharmaceutical approach contrasts sharply with state-level operators who have relied on regulatory loopholes rather than federal compliance.
The current regulatory crisis stems from what MMJ characterizes as seven years of DEA paralysis, during which the agency targeted compliant scientists while ignoring the synthetic THC explosion. In 2025, the Department of Justice conceded that the DEA's internal Administrative Law Judge system violated the Constitution, confirming MMJ's position that the agency's obstruction has been unlawful.
Path Forward for Cannabis Medicine
With the gray market facing elimination and courts affirming federal supremacy, MMJ International Holdings (search) is calling on President Trump and DEA Administrator Terry Cole to restore scientific integrity by immediately approving MMJ BioPharma Cultivation (search)'s DEA registration under the 60-day statutory mandate and creating a DEA Medical Research Division to separate scientific licensing from criminal enforcement.
"Federal enforcement isn't the enemy of science," Boise concluded. "It's what clears the field for legitimate research. MMJ is the compliant blueprint for the next generation of cannabis medicine."
The regulatory transformation represents a fundamental shift from state-level cannabis operations toward federally compliant pharmaceutical development, with MMJ International Holdings (search) positioned as a rare example of full regulatory compliance in advance of the industry-wide crackdown.